Summary
Diagnosing cancer as early as possible is one of the most powerful strategies in modern medicine to improve
human well-being. Antibodies (Abs) are excellent molecules that can be used to target specific tumors. As Abs
require hours to days for accumulating on tumor surfaces, the use of Abs for nuclear imaging (such as PET
imaging) is limited by the short half-lives of popular radioisotopes. Therefore, we plan to move the step of radiolabeling
from the bench to the tumor itself. However, the entanglement of Abs with an artificial chemical probe is
one of the most promising but at the same time one of the most technically challenging developmental areas in
biotechnology. Our unique approach is based on the production of “hybrid-Abs”, which combine in only one “click”
step the power of synthetic chemistry with the best of biology (“custom-biologics”). Our unique selling points are
ultra-fast, exceptional bioorthogonal and specific labeling reactions in living organism as well as a both-sided
modularity of the connection between Abs and chemical probe. By doing so, high contrast visualization of the
cancer will become possible.
human well-being. Antibodies (Abs) are excellent molecules that can be used to target specific tumors. As Abs
require hours to days for accumulating on tumor surfaces, the use of Abs for nuclear imaging (such as PET
imaging) is limited by the short half-lives of popular radioisotopes. Therefore, we plan to move the step of radiolabeling
from the bench to the tumor itself. However, the entanglement of Abs with an artificial chemical probe is
one of the most promising but at the same time one of the most technically challenging developmental areas in
biotechnology. Our unique approach is based on the production of “hybrid-Abs”, which combine in only one “click”
step the power of synthetic chemistry with the best of biology (“custom-biologics”). Our unique selling points are
ultra-fast, exceptional bioorthogonal and specific labeling reactions in living organism as well as a both-sided
modularity of the connection between Abs and chemical probe. By doing so, high contrast visualization of the
cancer will become possible.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/790139 |
| Start date: | 01-06-2018 |
| End date: | 30-11-2019 |
| Total budget - Public funding: | 150 000,00 Euro - 150 000,00 Euro |
Cordis data
Original description
Diagnosing cancer as early as possible is one of the most powerful strategies in modern medicine to improvehuman well-being. Antibodies (Abs) are excellent molecules that can be used to target specific tumors. As Abs
require hours to days for accumulating on tumor surfaces, the use of Abs for nuclear imaging (such as PET
imaging) is limited by the short half-lives of popular radioisotopes. Therefore, we plan to move the step of radiolabeling
from the bench to the tumor itself. However, the entanglement of Abs with an artificial chemical probe is
one of the most promising but at the same time one of the most technically challenging developmental areas in
biotechnology. Our unique approach is based on the production of “hybrid-Abs”, which combine in only one “click”
step the power of synthetic chemistry with the best of biology (“custom-biologics”). Our unique selling points are
ultra-fast, exceptional bioorthogonal and specific labeling reactions in living organism as well as a both-sided
modularity of the connection between Abs and chemical probe. By doing so, high contrast visualization of the
cancer will become possible.
Status
CLOSEDCall topic
ERC-2017-PoCUpdate Date
27-04-2024
Images
No images available.
Geographical location(s)
